Why the study?
Does the addition of a biomarker score (NT-proBNP, CRP, and sensitive troponin I) to a conventional risk model improve 10-year risk estimation for cardiovascular events in middle-aged European populations?
Does the addition of a biomarker score (NT-proBNP, CRP, and sensitive troponin I) to a conventional risk model improve 10-year risk estimation for cardiovascular events in middle-aged European populations?
Adding a biomarker score of NT-proBNP, CRP, and sensitive troponin I to conventional risk models improves 10-year cardiovascular risk prediction in middle-aged European populations.
May refine 10-year CV risk estimates in Europeans; leaves open whether it improves outcomes or warrants practice change.
The addition of a biomarker score including N-terminal pro-brain natriuretic peptide, C-reactive protein, and sensitive troponin I to a conventional risk model improved 10-year risk estimation for cardiovascular events in 2 middle-aged European populations. Further validation is needed in other populations and age groups.
No takes yet. Share an insight, caveat, or question.
Blankenberg et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: